Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss of $0.78/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
March 5, 2020 4:02 PM EST- Cash and cash equivalents totaled approximately $306 million at December 31, 2019 -
- Positive AURORA Phase 3 results with voclosporin enabling an NDA submission for the treatment of lupus nephritis (LN) by the end of the second quarter 2020 -
- Continued build out of a top-tier commercial team, highlighted by the appointment of Max Colao, Chief Commercial Officer, focused on launch activities -
- AUDREY Phase2/3 Dry Eye Study remains on-track with results anticipated during the second half of 2020 -
VICTORIA, British Columbia--(BUSINESS... More
